Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
dc.contributor.author | Carneiro, Simone Pinto | |
dc.contributor.author | Carvalho, Karen Vitor | |
dc.contributor.author | Soares, Rodrigo Dian de Oliveira Aguiar | |
dc.contributor.author | Carneiro, Cláudia Martins | |
dc.contributor.author | Andrade, Milton Hércules Guerra de | |
dc.contributor.author | Duarte, Rafael Silva | |
dc.contributor.author | Santos, Orlando David Henrique dos | |
dc.date.accessioned | 2019-03-27T17:21:38Z | |
dc.date.available | 2019-03-27T17:21:38Z | |
dc.date.issued | 2019 | |
dc.description.abstract | Tuberculosis is an infectious bacterial disease that causes millions of deaths worldwide. Current treatment recommended by WHO is effective, however it is an extensive and arduous process associated to severe adverse effects, which induces a low patient compliance and the emerging of multidrug resistant tuberculosis. Thus, as a main goal of this study, rifampicin nanoparticles were surface functionalized with a tuftsin-modifed peptide to selectively recognize receptors located on infected alveolar macrophages, enhancing nanoparticles uptake by these cells and improving antimycobacterial activity. A tuftsin-based modified peptide was synthesized and successfully attached to nanoparticles interface (NP-pRIF). In parallel, nanoparticles without peptide were also developed for comparison (NP-RIF). Physicochemical characterization demonstrated that stable and monodisperse nanodelivery systems were obtained, with a controlled drug release profile and non-cytotoxic potential. Moreover, nanoparticles containing peptide were significantly more internalized by macrophages than nanoparticles without peptide over a wide range of time. Both nanoparticles were 2-fold more effective against M. tuberculosis than free rifampicin, suggesting NP-pRIF as a promising strategy for the management of tuberculosis treatment. | pt_BR |
dc.identifier.citation | CARNEIRO, S. P. et al. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity. Colloids and Surfaces B: Biointerfaces, v. 175, p. 306-313, mar. 2019. Disponível em: <https://www.sciencedirect.com/science/article/pii/S092777651830883X?via%3Dihub>. Acesso em: 21 fev. 2019. | pt_BR |
dc.identifier.issn | 09277765 | |
dc.identifier.uri | http://www.repositorio.ufop.br/handle/123456789/10842 | |
dc.identifier.uri2 | https://www.sciencedirect.com/science/article/pii/S092777651830883X?via%3Dihub#! | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.rights | restrito | pt_BR |
dc.subject | Modified-tuftsin | pt_BR |
dc.subject | Tuberculosis | pt_BR |
dc.title | Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity. | pt_BR |
dc.type | Artigo publicado em periodico | pt_BR |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- ARTIGO_FunctionalizedRifampicinLoaded.pdf
- Tamanho:
- 684.3 KB
- Formato:
- Adobe Portable Document Format
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 924 B
- Formato:
- Item-specific license agreed upon to submission
- Descrição: